This paragraph from the annual report suggests a deal is not likely..
Although partnering remains an important commercial objective, we realistically have at least 12 – 18 months of significant FDA-‐directed clinical development before the lead asset is sufficiently de-‐risked to attract the commercial interest it truly deserves.
